SUPERNUS PHARMACEUTICALS, INC. Interest Income, Other
SUPERNUS PHARMACEUTICALS, INC. (SUPN) reported Interest Income, Other of $18.70 million for the 12-month period ending 2020-12-31, per its 10-K filed 2021-03-08.
Discontinued › Income Statement › Other Income
us-gaap:InterestIncomeOther · last filed 2021-03-08
- SUPERNUS PHARMACEUTICALS, INC. interest income, other for the quarter ending 2020-03-31 was $5.78M, a 23.41% increase year-over-year.
- SUPERNUS PHARMACEUTICALS, INC. interest income, other for the quarter ending 2019-12-31 was $5.97M, a 32.23% increase year-over-year.
- SUPERNUS PHARMACEUTICALS, INC. interest income, other for the quarter ending 2019-09-30 was $5.52M, a 23.81% increase year-over-year.
- SUPERNUS PHARMACEUTICALS, INC. interest income, other for the quarter ending 2019-06-30 was $5.45M, a 48.83% increase year-over-year.
- SUPERNUS PHARMACEUTICALS, INC. interest income, other for fiscal 2020 was $18.70M, a 13.50% decline from fiscal 2019.
- SUPERNUS PHARMACEUTICALS, INC. interest income, other for fiscal 2019 was $21.62M, a 56.20% increase from fiscal 2018.
- SUPERNUS PHARMACEUTICALS, INC. interest income, other for fiscal 2018 was $13.84M, a 383.34% increase from fiscal 2017.
- SUPERNUS PHARMACEUTICALS, INC. interest income, other for fiscal 2017 was $2.86M.
| Period end | Interest Income, Other 3 month | Interest Income, Other 6 month | Interest Income, Other 9 month | Interest Income, Other 12 month |
|---|---|---|---|---|
| 2020-12-31 | $18.70M 10-K · filed 2021-03-08 | |||
| 2020-03-31 | $5.78M 10-Q · filed 2020-05-15 | $11.74M derived: sum of 2 quarters · filed 2021-03-08 | $17.27M derived: sum of 3 quarters · filed 2021-03-08 | $22.72M derived: sum of 4 quarters · filed 2021-03-08 |
| 2019-12-31 | $5.97M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-08 | $11.49M derived: sum of 2 quarters · filed 2021-03-08 | $16.94M derived: sum of 3 quarters · filed 2021-03-08 | $21.62M 10-K · filed 2021-03-08 |
| 2019-09-30 | $5.52M 10-Q · filed 2019-11-08 | $10.98M derived: sum of 2 quarters · filed 2019-11-08 | $15.66M 10-Q · filed 2019-11-08 | $20.17M derived: sum of 4 quarters · filed 2021-03-08 |
| 2019-06-30 | $5.45M 10-Q · filed 2019-08-09 | $10.13M 10-Q · filed 2019-08-09 | $14.65M derived: sum of 3 quarters · filed 2021-03-08 | $19.11M derived: sum of 4 quarters · filed 2021-03-08 |
| 2019-03-31 | $4.68M 10-Q · filed 2020-05-15 | $9.19M derived: sum of 2 quarters · filed 2021-03-08 | $13.65M derived: sum of 3 quarters · filed 2021-03-08 | $17.32M derived: sum of 4 quarters · filed 2021-03-08 |
| 2018-12-31 | $4.51M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-08 | $8.97M derived: sum of 2 quarters · filed 2021-03-08 | $12.64M derived: sum of 3 quarters · filed 2021-03-08 | $13.84M 10-K · filed 2021-03-08 |
| 2018-09-30 | $4.46M 10-Q · filed 2019-11-08 | $8.13M derived: sum of 2 quarters · filed 2019-11-08 | $9.33M 10-Q · filed 2019-11-08 | |
| 2018-06-30 | $3.66M 10-Q · filed 2019-08-09 | $4.87M 10-Q · filed 2019-08-09 | ||
| 2018-03-31 | $1.21M 10-Q · filed 2019-05-10 | |||
| 2017-12-31 | $2.86M 10-K · filed 2020-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |